SENSEI BIOTHERAPEUTICS INC (SNSE)
US81728A1088 - Common Stock
SNSE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. SNSE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNSE is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SNSE had negative earnings in the past year.
In the past year SNSE has reported a negative cash flow from operations.
In the past 5 years SNSE always reported negative net income.
SNSE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SNSE has a Return On Assets (-49.61%) which is in line with its industry peers.
The Return On Equity of SNSE (-56.84%) is better than 63.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.61% | ||
| ROE | -56.84% | ||
| ROIC | N/A |
ROA(3y)-36.97%
ROA(5y)-383.39%
ROE(3y)-41.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, SNSE has less shares outstanding
Compared to 5 years ago, SNSE has less shares outstanding
Compared to 1 year ago, SNSE has a worse debt to assets ratio.
2.2 Solvency
SNSE has an Altman-Z score of -5.60. This is a bad value and indicates that SNSE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SNSE (-5.60) is worse than 63.81% of its industry peers.
SNSE has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
SNSE has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: SNSE outperforms 45.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.6 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 10.90 indicates that SNSE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.90, SNSE belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
A Quick Ratio of 10.90 indicates that SNSE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.90, SNSE belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.9 | ||
| Quick Ratio | 10.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.27% over the past year.
EPS 1Y (TTM)20.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SNSE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.96%
EPS Next 2Y3.3%
EPS Next 3Y7.13%
EPS Next 5Y-2.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNSE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.3%
EPS Next 3Y7.13%
5. Dividend
5.1 Amount
No dividends for SNSE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENSEI BIOTHERAPEUTICS INC
NASDAQ:SNSE (11/21/2024, 7:24:30 PM)
After market: 0.5 +0.02 (+4.17%)0.48
-0.02 (-3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.07M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.61% | ||
| ROE | -56.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.9 | ||
| Quick Ratio | 10.9 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)20.27%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y6.96%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y